TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37355035

Group type: EXPERIMENTAL
Intervention: Technology-assisted intervention (12-week program including 3 center-based supervised exercise sessions, a fitness watch, 6 educational videos, and weekly video calls)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Technology-assisted intervention
Number of subjects: 28

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 28
Study: 37355043

Group type: EXPERIMENTAL
Intervention: efinopegdutide 10 mg weekly
Number of subjects: 145

Group type: COMPARATOR
Intervention: semaglutide 1 mg weekly
Number of subjects: 145
Study: 37355044

Group type: EXPERIMENTAL
Intervention: Decompression with instrumented fusion
Number of subjects: 267

Group type: COMPARATOR
Intervention: Decompression alone
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 267
Study: 37355155

Group type: EXPERIMENTAL
Intervention: AWARE (Motivational Interviewing-based group intervention)
Number of subjects: 276

Group type: COMPARATOR
Intervention: Usual care (Control group)
Number of subjects: 276
Study: 37355263

Group type: EXPERIMENTAL
Intervention: Multimodal occupational therapy including patient education, hand exercises, assistive devices and orthoses (n=90)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Usual care receiving only information on OA (n=90)
Number of subjects: 180
Study: 37355267

Group type: EXPERIMENTAL
Intervention: Remote ischaemic preconditioning (RIPC) - four cycles of cuff inflation for 5 min to 200 mm Hg and deflation for 5 min.
Number of subjects: 766

Group type: EXPERIMENTAL
Intervention: Remote ischaemic preconditioning (RIPC)
Number of subjects: 766

Group type: COMPARATOR
Intervention: Control treatment - identical-looking cuff placed around the arm but not inflated.
Number of subjects: 766
Study: 37355270

Group type: EXPERIMENTAL
Intervention: 30 minutes of in-bed cycling in addition to routine physiotherapy (PT), 5 days per week, up to 28 days maximum
Number of subjects: 360

Group type: COMPARATOR
Intervention: Routine physiotherapy (PT) alone
Number of subjects: 360
Study: 37355275

Group type: EXPERIMENTAL
Intervention: Systematic evaluation of staging and activity of invasive fungal infection (IFI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Anatomy-based imaging
Number of subjects: 0
Study: 37355274

Group type: EXPERIMENTAL
Intervention: Postpartum depression screening by family paediatricians using Whooley questions during visits at 60-90 days and 5-7 months after childbirth.
Number of subjects: 2203

Group type: EXPERIMENTAL
Intervention: Maternal postnatal depressive symptoms
Number of subjects: 2203

Group type: EXPERIMENTAL
Intervention: Child sleeping disorders at 3 months
Number of subjects: 2203

Group type: EXPERIMENTAL
Intervention: Having a likely depressed partner
Number of subjects: 2203
Study: 37355412

Group type: EXPERIMENTAL
Intervention: Remifentanil alone
Number of subjects: 2

Group type: COMPARATOR
Intervention: Propofol alone
Number of subjects: 2

Group type: COMPARATOR
Intervention: Combination of remifentanil and propofol
Number of subjects: 2
Study: 37355418

Group type: EXPERIMENTAL
Intervention: Melflufen plus dexamethasone
Number of subjects: 495

Group type: COMPARATOR
Intervention: Pomalidomide
Number of subjects: 495
Study: 37355476

Group type: EXPERIMENTAL
Intervention: High PAHCO profile (46% of patients)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Moderate PAHCO profile (48% of patients)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Low PAHCO profile (5% of patients)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Profile one (32% of patients)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Profile two (40% of patients)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Profile three (15% of patients)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: High PAHCO profile
Number of subjects: 98
Study: 37355526

Group type: EXPERIMENTAL
Intervention: Neoadjuvant systemic therapy (NST)
Number of subjects: 500
Study: 37355565

Group type: EXPERIMENTAL
Intervention: Propofol sedation during endoscopy
Number of subjects: 30
Study: 37355583

Group type: EXPERIMENTAL
Intervention: Protocol deviations reported during the trial
Number of subjects: 5407

Group type: EXPERIMENTAL
Intervention: Preventive actions taken in response to protocol deviations
Number of subjects: 5407
Study: 37355622

Group type: EXPERIMENTAL
Intervention: Problem-Solving Pain to Enhance Living Well intervention (including video modules, activity trackers, and nurse consultations)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Problem-Solving Pain to Enhance Living Well intervention
Number of subjects: 40
Study: 37355803

Group type: COMPARATOR
Intervention: Brain Health Group (BHG) - an attention control condition focused on brain health education and self-management.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Brain Health Group (BHG)
Number of subjects: 0
Study: 37356033

Group type: EXPERIMENTAL
Intervention: 15 mg pegozafermin weekly
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: 30 mg pegozafermin weekly
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: 44 mg pegozafermin once every 2 weeks
Number of subjects: 222

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 222
Study: 37356038

Group type: EXPERIMENTAL
Intervention: Crizanlizumab (5 mg/kg) plus standard of care
Number of subjects: 422

Group type: COMPARATOR
Intervention: Standard of care alone
Number of subjects: 422
Study: 37356066

Group type: EXPERIMENTAL
Intervention: Once-weekly insulin icodec
Number of subjects: 984

Group type: COMPARATOR
Intervention: Once-daily insulin glargine U100
Number of subjects: 984

Group type: EXPERIMENTAL
Intervention: Combined clinically significant or severe hypoglycemia with insulin icodec
Number of subjects: 984

Group type: COMPARATOR
Intervention: Combined clinically significant or severe hypoglycemia with insulin glargine U100
Number of subjects: 984
Study: 37356075

Group type: EXPERIMENTAL
Intervention: Upadacitinib 30 mg
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 mg
Number of subjects: 272

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 272
Study: 37356078

Group type: EXPERIMENTAL
Intervention: Ripretinib as a fourth-line treatment
Number of subjects: 240
Study: 37356256

Group type: EXPERIMENTAL
Intervention: Ocrelizumab (open-label, single-arm, multicenter, phase IV study)
Number of subjects: 182
Study: 37356492

Group type: EXPERIMENTAL
Intervention: Intracanalicular Dexamethasone Insert
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 37356500

Group type: EXPERIMENTAL
Intervention: Maternal preconception BMI (mean 23.6, SD 4.4)
Number of subjects: 4733
Study: 37356515

Group type: EXPERIMENTAL
Intervention: Higher Physical Anhedonia Scale (PAS) scores
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Increasing Inventory for Depressive Symptoms (IDS) scores
Number of subjects: 98
Study: 37356549

Group type: EXPERIMENTAL
Intervention: Total sulfur amino acids (TSAA) requirement in older men
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Total sulfur amino acids (TSAA) requirement in older women
Number of subjects: 0
Study: 37356561

Group type: EXPERIMENTAL
Intervention: Lozenge containing Lacticaseibacillus rhamnosus, LGG® (DSM33156), Lactobacillus paracasei subsp. paracasei, L. CASEI 431® (DSM33451) and prebiotic (arginine 2%)
Number of subjects: 343

Group type: COMPARATOR
Intervention: Placebo lozenge without arginine or probiotics
Number of subjects: 343
Study: 37356618

Group type: EXPERIMENTAL
Intervention: New-onset chronic pain
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Secondary pain
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Primary chronic pain
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Pain intensity
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Impact on daily life
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Associated conditions
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Intubation
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Specialized pain centre follow-up
Number of subjects: 143
Study: 37356632

Group type: EXPERIMENTAL
Intervention: Topical tranexamic acid (TXA) application, 1.25 g of TXA powder sprayed endoscopically on the ulcer, alongside 3 days of high-dose (8 mg/h) continuous infusion proton pump inhibitor therapy.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard group (no TXA), alongside 3 days of high-dose (8 mg/h) continuous infusion proton pump inhibitor therapy.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Topical tranexamic acid (TXA) application
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard group (no TXA)
Number of subjects: 60
Study: 37356634

Group type: EXPERIMENTAL
Intervention: US capsule endoscopy (USCE)
Number of subjects: 20
Study: 37356707

Group type: EXPERIMENTAL
Intervention: Restrictive visitation policies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard visitation policies
Number of subjects: 0
Study: 37356708

Group type: EXPERIMENTAL
Intervention: 15 mL ExoFlo
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study: 37356710

Group type: EXPERIMENTAL
Intervention: More intensive strategies for radiographic surveillance
Number of subjects: 2049

Group type: COMPARATOR
Intervention: Less intensive strategies for radiographic surveillance
Number of subjects: 2049
Study: 37356876

Group type: EXPERIMENTAL
Intervention: Faster aspart insulin
Number of subjects: 50
Study: 37357024

Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37357092

Group type: EXPERIMENTAL
Intervention: Psychiatric support for PTSD
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no psychiatric support)
Number of subjects: 0
Study: 37357331

Group type: EXPERIMENTAL
Intervention: Camelina enriched crackers (35 g, twice daily for 12 weeks)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo crackers (35 g, twice daily for 12 weeks)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Camelina enriched crackers
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo crackers
Number of subjects: 66
Study: 37357351

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 37357807

Group type: EXPERIMENTAL
Intervention: 100 mg iron supplements taken in the morning with ascorbic acid (AA)
Number of subjects: 34

Group type: COMPARATOR
Intervention: 100 mg iron supplements taken at different times of day without ascorbic acid (AA)
Number of subjects: 34
Study: 37357811

Group type: EXPERIMENTAL
Intervention: Parent-mediated physical activity intervention (workshop group)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Parent-mediated physical activity intervention (online group)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 31
Study: 37357904

Group type: EXPERIMENTAL
Intervention: Moxidectin (8 mg) and Albendazole (400 mg)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Ivermectin (200 µg/kg) and Albendazole (400 mg)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Albendazole (400 mg) and Placebo
Number of subjects: 210
Study: 37357950

Group type: EXPERIMENTAL
Intervention: barecetamab monotherapy at 20 mg/kg IV every 3 weeks
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: barecetamab (20 mg/kg IV) and cetuximab (400 mg/m2) combination therapy
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: barecetamab at 1, 3, 5, 10, and 20 mg/kg IV on days 1 and 28 and weekly
Number of subjects: 33
Study: 37358048

Group type: EXPERIMENTAL
Intervention: Low-pressure pneumoperitoneum (7 mmHg)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Standard-pressure pneumoperitoneum (12 mmHg)
Number of subjects: 98
Study: 37358056

Group type: EXPERIMENTAL
Intervention: Use of generic 'you' in expressive writing
Number of subjects: 138
Study: 37358262

Group type: EXPERIMENTAL
Intervention: High & Increasing MVPA
Number of subjects: 577

Group type: EXPERIMENTAL
Intervention: Higher MVPA level at 12-month follow-up
Number of subjects: 577
Study: 37358545

Group type: EXPERIMENTAL
Intervention: Oral alcohol challenge
Number of subjects: 0

Group type: COMPARATOR
Intervention: Expectancy of alcohol analgesia
Number of subjects: 0
Study: 37358640

Group type: EXPERIMENTAL
Intervention: Idelalisib containing therapy
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Idelalisib after prior ibrutinib therapy
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Idelalisib without prior ibrutinib therapy
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Idelalisib therapy
Number of subjects: 81
Study: 37358716

Group type: EXPERIMENTAL
Intervention: TBI-CareQOL measures
Number of subjects: 139
Study: 37358858

Group type: EXPERIMENTAL
Intervention: Standard-course therapy (another 5 days of antimicrobials)
Number of subjects: 664

Group type: COMPARATOR
Intervention: Short-course therapy (5 days of placebo)
Number of subjects: 664

Group type: COMPARATOR
Intervention: Short-course therapy
Number of subjects: 664

Group type: COMPARATOR
Intervention: Standard-course therapy and Short-course therapy
Number of subjects: 664
Study: 37358859

Group type: EXPERIMENTAL
Intervention: Butylphthalide (NBP)
Number of subjects: 1216

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1216
Study: 37358870

Group type: EXPERIMENTAL
Intervention: Semont-plus maneuver (SM-plus)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Epley maneuver (EM)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Single maneuver performed by physician (for both groups)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 195
Study: 37358883

Group type: EXPERIMENTAL
Intervention: Persuasive mobile health app
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Personalized tunneling
Number of subjects: 59
Study: 37358888

Group type: EXPERIMENTAL
Intervention: mHealth app SidekickHealth (social health game focusing on nutrition, mental health, and physical health)
Number of subjects: 304

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 304
Study: 37358908

Group type: EXPERIMENTAL
Intervention: KeepCalm app
Number of subjects: 20
Study: 37358916

Group type: EXPERIMENTAL
Intervention: IBI112 (subcutaneous 5-600 mg or intravenous 100 and 600 mg)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 37359242

Group type: EXPERIMENTAL
Intervention: Sotrastaurin 300 mg and Binimetinib 30 mg
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Sotrastaurin 200 mg and Binimetinib 45 mg
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Sotrastaurin and Binimetinib (combined)
Number of subjects: 38
Study: 37359465

Group type: EXPERIMENTAL
Intervention: Parent-led therapist-assisted intervention (SC TF-CBT)
Number of subjects: 0
Study: 37359866

Group type: EXPERIMENTAL
Intervention: Let's Talk about Children intervention
Number of subjects: 0
Study: 37359884

Group type: EXPERIMENTAL
Intervention: Surf Therapy
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Hike Therapy
Number of subjects: 96
Study: 37360058

Group type: EXPERIMENTAL
Intervention: Short-term intensive parent training program
Number of subjects: 111

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 111
Study: 37360060

Group type: EXPERIMENTAL
Intervention: Responsive caregiving intervention educating parents about the developing brain and alternatives to corporal punishment
Number of subjects: 153

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 153
Study: 37360346

Group type: EXPERIMENTAL
Intervention: Antioxidant treatment with lipoic acid
Number of subjects: 114
Study: 37360348

Group type: EXPERIMENTAL
Intervention: Ergotact training program
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control training group (Self)
Number of subjects: 28
Study: 37360352

Group type: EXPERIMENTAL
Intervention: DOSE protocol (higher intensity walking)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual Care (control group)
Number of subjects: 0
Study: 37360762

Group type: EXPERIMENTAL
Intervention: Compassionate Mind Training for Caregivers (CMT-Care Homes)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 127
Study: 37360811

Group type: EXPERIMENTAL
Intervention: Immersive virtual reality (IVR) intervention incorporating Japanese garden aesthetics, relaxation, and elements of Erickson's psychotherapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Low-intensity general fitness training sessions (twice a week for four weeks)
Number of subjects: 60
Study: 37360864

Group type: EXPERIMENTAL
Intervention: Convidecia (heterologous third dose)
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Convidecia (heterologous second dose)
Number of subjects: 299

Group type: COMPARATOR
Intervention: CoronaVac (three doses)
Number of subjects: 299

Group type: COMPARATOR
Intervention: CoronaVac (second dose)
Number of subjects: 299

Group type: COMPARATOR
Intervention: CoronaVac (third dose)
Number of subjects: 299
Study: 37361167

Group type: EXPERIMENTAL
Intervention: Personal aptitudes (activation, health literacy, personality traits)
Number of subjects: 16
Study: 37361203

Group type: EXPERIMENTAL
Intervention: Astragali Radix
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 37361220

Group type: EXPERIMENTAL
Intervention: Voriconazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clarithromycin
Number of subjects: 0
Study: 37361338

Group type: EXPERIMENTAL
Intervention: Qualitative Study Within A Trial (Qual-SWAT)
Number of subjects: 0
Study: 37361343

Group type: EXPERIMENTAL
Intervention: Patient-level intervention
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Multi-level intervention
Number of subjects: 42

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 42
Study: 37361483

Group type: EXPERIMENTAL
Intervention: Psychophysiologic symptom relief therapy (PSRT) during a 13 week (approximately 44 hour) course.
Number of subjects: 23
Study: 37361536

Group type: EXPERIMENTAL
Intervention: DiaCompanion I (intervention group)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 216
Study: 37361617

Group type: EXPERIMENTAL
Intervention: PVI + ablation of EGF-identified extra-PV sources of AF
Number of subjects: 85

Group type: COMPARATOR
Intervention: PVI only
Number of subjects: 85
Study: 37362184

Group type: EXPERIMENTAL
Intervention: MORE + JITAI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: JITAI-initiated mindfulness practice
Number of subjects: 0

Group type: COMPARATOR
Intervention: SG (control group)
Number of subjects: 0
Study: 37363124

Group type: EXPERIMENTAL
Intervention: 2-day Advanced Cardiac Life Support course followed by 3-day Vital Anaesthesia Simulation Training Course
Number of subjects: 47
Study: 37363177

Group type: EXPERIMENTAL
Intervention: Previous suicidal attempt
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TAS-20
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BDI-13
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clinical features (alcohol dependence, suicide intent, hopelessness)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Previous SA, depression, and alexithymia
Number of subjects: 0
Study: 37363275

Group type: EXPERIMENTAL
Intervention: Digital assessment screening
Number of subjects: 751

Group type: COMPARATOR
Intervention: Physical assessment screening
Number of subjects: 751
Study: 37363832

Group type: EXPERIMENTAL
Intervention: Sleeve Gastrectomy
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Roux-en-Y Gastric Bypass
Number of subjects: 9

Group type: COMPARATOR
Intervention: Preoperative Baseline
Number of subjects: 9
Study: 37363967

Group type: EXPERIMENTAL
Intervention: Laxative use
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Vomiting frequency
Number of subjects: 265

Group type: COMPARATOR
Intervention: No laxative use
Number of subjects: 265
Study: 37363965

Group type: EXPERIMENTAL
Intervention: Tucatinib, Letrozole, and Palbociclib (TLP combination)
Number of subjects: 42
Study: 37363989

Group type: EXPERIMENTAL
Intervention: Psychosocial VH interview
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Educational VH interview
Number of subjects: 94

Group type: COMPARATOR
Intervention: Standard VH interview
Number of subjects: 94
Study: 37363992

Group type: EXPERIMENTAL
Intervention: Dostarlimab 500 mg every 3 weeks for four cycles, then 1,000 mg every 6 weeks until progression
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Dostarlimab
Number of subjects: 314
Study: 37364000

Group type: EXPERIMENTAL
Intervention: Androgen receptor pathway inhibitors (ARPI; e.g., enzalutamide, abiraterone acetate)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: RNA sequencing (RNA-seq) analysis
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Whole-exome sequencing (WES) analysis
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Androgen receptor pathway inhibitors (ARPI)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Low AR activity, activation of stemness programs, and Hedgehog pathway
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Acquired resistance
Number of subjects: 59
Study: 37364004

Group type: EXPERIMENTAL
Intervention: DISCO App
Number of subjects: 0
Study: 37364021

Group type: EXPERIMENTAL
Intervention: Web-based training module for physician communication about clinical trials
Number of subjects: 19
Study: 37364033

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral-Based Hybrid Telerehabilitation Intervention (GOALS/Metas)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual Care Physical Therapy
Number of subjects: 0
Study: 37364044

Group type: EXPERIMENTAL
Intervention: Standard plus timing and coordination training intervention
Number of subjects: 166

Group type: COMPARATOR
Intervention: Standard strength and endurance intervention
Number of subjects: 166
Study: 37364133

Group type: EXPERIMENTAL
Intervention: Teduglutide (0.05 mg/kg/day)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Standard of Care (SoC)
Number of subjects: 29
Study: 37364218

Group type: EXPERIMENTAL
Intervention: Trastuzumab combined with ramucirumab and paclitaxel
Number of subjects: 50
Study: 37364220

Group type: EXPERIMENTAL
Intervention: Aspirin treatment for high-risk colorectal cancer
Number of subjects: 1587

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 1587
Study: 37364223

Group type: EXPERIMENTAL
Intervention: Intermittent relacorilant + nab-paclitaxel
Number of subjects: 178

Group type: COMPARATOR
Intervention: nab-paclitaxel monotherapy
Number of subjects: 178
Study: 37364268

Group type: EXPERIMENTAL
Intervention: 8-hour Time-Restricted Eating (TRE)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Calorie Restriction (CR)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control (eating over a period of 10 or more hours per day)
Number of subjects: 90